Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device
2 other identifiers
observational
20
1 country
1
Brief Summary
The goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone SC or RC and their impact on the quality of life of these participants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 8, 2025
CompletedFirst Posted
Study publicly available on registry
April 15, 2025
CompletedStudy Start
First participant enrolled
October 31, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2028
October 23, 2025
October 1, 2025
1.2 years
April 8, 2025
October 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Survival (OS)
Through study completion; an average of 1 year.
Study Arms (1)
Colon Cancer
Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life. Participants in this study will be over after all study procedures are completed.
Interventions
Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life. Participants in this study will be over after all study procedures are completed.
Eligibility Criteria
MD Anderson Cancer Center
You may qualify if:
- Both men and women of all races and ethnic groups are eligible for this trial who meet the above criteria.
You may not qualify if:
- Children will not be enrolled in this study.
- Pregnant women will not be enrolled in this study.
- Cognitively impaired subjects will not be enrolled in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2025
First Posted
April 15, 2025
Study Start
October 31, 2025
Primary Completion (Estimated)
December 30, 2026
Study Completion (Estimated)
December 30, 2028
Last Updated
October 23, 2025
Record last verified: 2025-10